Immunotherapy side effect may be reversible: thyroid drug taper trial launches

NCT ID NCT07421869

Recruiting now Disease control Sponsor: Seoul National University Bundang Hospital Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study looks at whether hypothyroidism caused by immune checkpoint inhibitors (a type of cancer immunotherapy) can go away after stopping the immunotherapy. 107 adult cancer patients who developed hypothyroidism during treatment and are now off immunotherapy will gradually reduce their thyroid medication (levothyroxine) every 3 months. The goal is to see how many can stop the medication completely and for how long.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Levothyroxine tapering
What this could lead to: If successful, this could show that some patients can safely stop thyroid medication after finishing immunotherapy, reducing lifelong drug burden.
What could go wrong: This is a small, early-phase study without a control group. Many patients may still need lifelong thyroid hormone, and the tapering process could cause temporary symptoms.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPOTHYROIDISM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hypothyroidism

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HYPOTHYROIDISM

Contacts and locations

Locations

Department of Internal Medicine, Seoul National University Bundang Hospital
RECRUITING

Seongnam-si, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.